Kangle Guardian announces the unblinding of the Phase III clinical trial of the trivalent HPV vaccine, and the interim analysis is as expected.

Jinshi data, August 14th, Kang Lewei announced that the independent data monitoring committee for the phase III protection efficacy clinical trial of the recombinant trivalent human papillomavirus (16/18/58 type) vaccine (Escherichia coli) independently developed by Kang Lewei has completed the mid-term analysis unblinding, main efficacy indicators and safety assessment, and the results meet expectations.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 1
  • Repost
  • Share
Comment
0/400
GateUser-3e254a9cvip
· 2024-08-14 04:41
All in All in 🙌
View OriginalReply0
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)